PROs In Diabetes: FDA Panel Wanted Data Proving Insulin Icodec’s ‘Theoretical’ Benefits In Type 1

 
• By Sue Sutter
  
Once a week
Novo failed to prove the benefits of once-weekly basal insulin dosing. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers